Centhaquine citrate is under clinical development by Pharmazz and currently in Phase I for Acute Renal Failure (ARF) (Acute Kidney Injury). According to GlobalData, Phase I drugs for Acute Renal Failure (ARF) (Acute Kidney Injury) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Centhaquine citrate LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Centhaquine citrate overview
Centhaquine (Lyfaquin) is a quinoline derivative. It is formulated as solution for intravenous route of administration. Lyfaquin is indicated as transformational therapy for hypovolemic shock.
PMZ-2010 (centhaquine) is under development for the treatment of resuscitation in hypovolemic shock, cardiac arrest, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), hemorrhagic shock-induced acute kidney injury and COVID-19 acute respiratory distress syndrome. The drug candidate is administered through intravenous route. It is a quinoline derivative. It acts by targeting alpha-2 adrenergic receptor and alpha 1 adrenergic receptor.
It was under development for post-operative pain.
Pharmazz overview
Pharmazz, Inc.(Pharmazz) is an biopharmaceutical company with an approved product, promising drug pipeline focused on discovering, acquiring, developing, and commercializing therapeutics. It is headquartered in Willowbrook, Illinois, the US.
For a complete picture of Centhaquine citrate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
